Novo's 10% Hit Isn't the Story-Lilly's Take The Race While Novo Cuts Prices

CagriSema's miss hit Novo's "best-in-class" claim at once

This was more than an ordinary clinical setback. Novo did not simply miss a trial endpoint; it lost a head-to-head argument it needed to win. Novo shares fell over 10% Monday after CagriSema did not meet its primary goal, and the efficacy read was unfavorable: patients on CagriSema lost 23.0% of body weight at 84 weeks versus 25.5% with tirzepatide. In obesity, that kind of gap matters because investors are looking for a clear leader, not just a competent option.

Why the selloff hit harder

The result landed on top of existing pressure. Novo stock was already trading at a multi-year low after a series of disappointing announcements, so this did not arrive as an isolated event. That helps explain why the market reaction was less about one drug candidate and more about Novo's standing in the obesity race.

Why Lilly's lead looks stronger

The setback went beyond Novo's own numbers. Its trial appeared to show weight loss with Zepbound was better than even some of Lilly's own data had shown. That strengthens the case that Lilly is gaining ground on efficacy, not just market excitement. Novo says it is still exploring higher-dose combinations, but until that follow-up data are available, the immediate effect is a weaker competitive narrative.